- Home
- TFX vs IONS Comparison
TFX vs IONS Comparison
Compare TFX & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFX
- IONS
- Stock Information
- Founded
- TFX 1943
- IONS 1989
- Country
- TFX United States
- IONS United States
- Employees
- TFX N/A
- IONS N/A
- Industry
- TFX Medical/Dental Instruments
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- TFX Health Care
- IONS Health Care
- Exchange
- TFX Nasdaq
- IONS Nasdaq
- Market Cap
- TFX 5.3B
- IONS 5.9B
- IPO Year
- TFX N/A
- IONS 1991
- Fundamental
- Price
- TFX $119.90
- IONS $43.00
- Analyst Decision
- TFX Hold
- IONS Buy
- Analyst Count
- TFX 10
- IONS 16
- Target Price
- TFX $176.50
- IONS $58.25
- AVG Volume (30 Days)
- TFX 536.7K
- IONS 2.0M
- Earning Date
- TFX 07-31-2025
- IONS 07-31-2025
- Dividend Yield
- TFX 1.13%
- IONS N/A
- EPS Growth
- TFX N/A
- IONS N/A
- EPS
- TFX 3.20
- IONS N/A
- Revenue
- TFX $3,010,144,000.00
- IONS $717,253,000.00
- Revenue This Year
- TFX $2.98
- IONS $7.98
- Revenue Next Year
- TFX $4.72
- IONS $16.09
- P/E Ratio
- TFX $37.45
- IONS N/A
- Revenue Growth
- TFX 0.29
- IONS N/A
- 52 Week Low
- TFX $115.94
- IONS $23.95
- 52 Week High
- TFX $249.91
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- TFX 45.92
- IONS 78.37
- Support Level
- TFX $117.41
- IONS $39.37
- Resistance Level
- TFX $123.97
- IONS $43.71
- Average True Range (ATR)
- TFX 2.51
- IONS 1.36
- MACD
- TFX 0.43
- IONS 0.44
- Stochastic Oscillator
- TFX 49.32
- IONS 92.05
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.